Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.
Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C.
Manuel M, et al. Among authors: perez s.
Oncoimmunology. 2012 Jul 1;1(4):432-440. doi: 10.4161/onci.19545.
Oncoimmunology. 2012.
PMID: 22754761
Free PMC article.